Tarsus to Report Fourth Quarter and Full-Year 2024 Financial Results on Tuesday, February 25, 2025

Rhea-AI Impact

(Neutral)

Rhea-AI Sentiment

(Neutral)

Rhea-AI Summary

Tarsus Pharmaceuticals (NASDAQ: TARS) has announced it will host a live webcast on Tuesday, February 25, 2025, at 5:00 a.m. PT / 8:00 a.m. ET to present its fourth quarter and full-year 2024 financial results along with a corporate update. The webcast will be available for participants to access online, and a recorded version will be posted on the company's website shortly after the event, remaining accessible for approximately 90 days.

News Market Reaction – TARS

-1.81%

1 alert

-1.81% News Effect

On the day this news was published, TARS declined 1.81%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

02/20/2025 - 05:00 PM

IRVINE, Calif., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that it will host a live webcast at 5:00 a.m. PT / 8:00 a.m. ET on Tuesday, February 25, 2025, to report its fourth quarter and full-year 2024 financial results and provide a corporate update.

Participants may access the webcast here. A recorded version of the call will be available on the website shortly after the completion of the webcast and will be archived there for approximately 90 days.

About Tarsus Pharmaceuticals, Inc.
Tarsus Pharmaceuticals, Inc. applies proven science and new technology to revolutionize treatment for patients, starting with eye care. Tarsus is advancing its pipeline to address several diseases with high unmet need across a range of therapeutic categories, including eye care and infectious disease prevention. XDEMVY^® (lotilaner ophthalmic solution, 0.25%) is FDA approved in the United States for the treatment of Demodex blepharitis. Tarsus is also developing TP-04 for the potential treatment of Ocular Rosacea and TP-05 as an oral tablet for the potential prevention of Lyme disease.

Media Contact:
Adrienne Kemp
Sr. Director, Corporate Communications
(949) 922-0801
AKemp@tarsusrx.com

Investor Contact:
David Nakasone
Head of Investor Relations
(949) 620-3223
DNakasone@tarsusrx.com

FAQ

When will Tarsus Pharmaceuticals (TARS) report Q4 and full-year 2024 earnings?

Tarsus Pharmaceuticals will report its Q4 and full-year 2024 financial results on Tuesday, February 25, 2025, at 5:00 a.m. PT / 8:00 a.m. ET.

How can investors access the TARS Q4 2024 earnings webcast?

Investors can access the live webcast through a link provided by the company. A recorded version will also be available on the company's website after the event.